[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY27416A1 - Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana - Google Patents

Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana

Info

Publication number
UY27416A1
UY27416A1 UY27416A UY27416A UY27416A1 UY 27416 A1 UY27416 A1 UY 27416A1 UY 27416 A UY27416 A UY 27416A UY 27416 A UY27416 A UY 27416A UY 27416 A1 UY27416 A1 UY 27416A1
Authority
UY
Uruguay
Prior art keywords
treatment
migrana
antimigranose
bibn4096
drugs
Prior art date
Application number
UY27416A
Other languages
English (en)
Inventor
Dr Doods
Dr Rudolf
Dr Eberlein
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27416A1 publication Critical patent/UY27416A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un método de tratamiento o prevención de la cefalea, migrana o cefaleas en racimo, método que comprende la co-administración de una cantidad terapéuticamente eficaz del compuesto A =1-(N2-(3,5-Dibromo-N- ((4-(3,4-dihidro-2(1H)-oxoquinazolin-3-il)-1-piperidinil)-carbonil)-D-tirosil)-L-lisil)-4 -(4-piridinil)-piperazina(BIBN4096BS) o una de sus sales fisiológicamente aceptables y una cantidad terapéuticamente eficaz de un segundo fármaco antimigranoso activo, particularmente sumatriptán, zolmitriptán o dihidroergotamina o una de sus sales fisiológicamente aceptables, así como a las correspondientes composiciones farmacéuticas y su preparación.
UY27416A 2001-08-17 2002-08-14 Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana UY27416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10139410A DE10139410A1 (de) 2001-08-17 2001-08-17 Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne

Publications (1)

Publication Number Publication Date
UY27416A1 true UY27416A1 (es) 2003-03-31

Family

ID=7695082

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27416A UY27416A1 (es) 2001-08-17 2002-08-14 Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana

Country Status (22)

Country Link
EP (1) EP1420790B1 (es)
JP (1) JP2005503382A (es)
KR (1) KR20040027892A (es)
CN (1) CN1543347A (es)
AR (1) AR036265A1 (es)
AT (1) ATE304854T1 (es)
BR (1) BR0211970A (es)
CA (1) CA2454083A1 (es)
CO (1) CO5560577A2 (es)
DE (2) DE10139410A1 (es)
EA (1) EA200400253A1 (es)
EC (1) ECSP044979A (es)
ES (1) ES2250733T3 (es)
HR (1) HRP20040150A2 (es)
HU (1) HUP0401484A3 (es)
IL (1) IL159879A0 (es)
MX (1) MXPA04001364A (es)
NO (1) NO20041024D0 (es)
PL (1) PL365482A1 (es)
UY (1) UY27416A1 (es)
WO (1) WO2003015787A1 (es)
ZA (1) ZA200400313B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
EP1374870A1 (en) * 2002-06-24 2004-01-02 Rita Dobmeyer Medication for the treatment or prevention of migraine
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005102322A1 (de) * 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
CN102526031A (zh) * 2010-12-27 2012-07-04 湖南九典制药有限公司 一种鼻腔内使用的舒马普坦药物组合物及其制备方法
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE266673T1 (de) * 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Also Published As

Publication number Publication date
CO5560577A2 (es) 2005-09-30
NO20041024D0 (no) 2004-02-16
DE60206289D1 (de) 2006-02-02
HUP0401484A2 (hu) 2004-12-28
WO2003015787A1 (en) 2003-02-27
EP1420790A1 (en) 2004-05-26
ES2250733T3 (es) 2006-04-16
CN1543347A (zh) 2004-11-03
IL159879A0 (en) 2004-06-20
KR20040027892A (ko) 2004-04-01
DE60206289T2 (de) 2006-06-08
AR036265A1 (es) 2004-08-25
ECSP044979A (es) 2004-04-28
BR0211970A (pt) 2004-09-21
EP1420790B1 (en) 2005-09-21
PL365482A1 (en) 2005-01-10
MXPA04001364A (es) 2004-05-27
HRP20040150A2 (en) 2004-06-30
JP2005503382A (ja) 2005-02-03
ATE304854T1 (de) 2005-10-15
DE10139410A1 (de) 2003-02-27
ZA200400313B (en) 2004-11-01
HUP0401484A3 (en) 2007-03-28
EA200400253A1 (ru) 2004-08-26
CA2454083A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
ATE401874T1 (de) Verabreichung von capsaicinoiden
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
PA8586501A1 (es) Tabletas dispersables que comprenden un derivado de acido benzoico
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
SE0302488D0 (sv) New combination
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
AR031679A1 (es) Una composicion farmaceutica
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
AR038858A1 (es) Combinacion
UY28251A1 (es) Uso del hidrocloruro de la base del principio activo 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2 (1h)- oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-pipperidin)-piperazina en combinación con sumatriptano para el tratamiento de la
MXPA05011064A (es) Combinaciones de paroxetina y [1-(r)-(3, 5-bis-trifluorometi l-fenil)-etil] -metilamida del acido 4-(s)- (4-acetil-piperazin -1-il)-2- (r)-(4-fluoro -2-metil- fenil)-piperidin -1-carboxilico para tratamiento de depresion y/o ansiedad.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141226